The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000385347
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
6/02/2026
Date registered
Help: Date registered
27/03/2026
Date last updated
Help: Date last updated
9/10/2026
Date data sharing statement initially provided
Help: Data sharing statement date
27/03/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
A study to assess safety, tolerability and pharmacokinetics of RTX-010/101/111 for participants with C9orf72-mediated Amyotrophic Lateral Sclerosis (ALS). Part 1C adults with C9orf72-mediated ALS only.
Scientific title
A Randomised, Open-Label, Multiple Dosing Study to assess safety, tolerability and pharmacokinetics of RTX-010/101/111 for participants with C9orf72-mediated Amyotrophic Lateral Sclerosis (ALS). Part 1C adults with C9orf72-mediated ALS only.
Additional trial identifiers [1] 316264 0
Nil
Universal Trial Number (UTN)
Trial acronym
Related trial records
This study is Part 1C following on from registration record ACTRN12625001215415 (Part 1A and 1B healthy participants)..

Health condition
Health condition(s) studied:
C9orf72-mediated Amyotrophic Lateral Sclerosis (ALS) 340299 0
Condition category
Condition code
Neurological 336494 336494 0 0
Neurodegenerative diseases

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
This is a multi-centre, open-label, multiple dosing of RTX-101 and RTX-111 conducted in adult participants with C9orf72-mediated Amyotrophic Lateral Sclerosis (ALS) designed to evaluate the safety, tolerability and PK of RTX-101 and RTX-111.

The treatments RTX-101 (comprised of 2 different medications) and RTX-111 (comprised of 3 different medications). 2 medications are white opaque gelatine capsules and 1 medication is a white tablet.

This part if the study is known as Part 1C.

In Part 1C, the participating clinical sites will contact patients (who are attending/registered at the clinic) diagnosed with C9orf72 ALS who would be considered eligible based on their medical history and study inclusion/exclusion criteria to determine if they may be interested in participating in the study.

The administration of RTX-101 and RTX-111 will be oral. The participants will be instructed to swallow the capsules or tablets whole and where applicable the clinical site/nursing staff will check their mouth afterwards to ensure they have swallowed the capsules. In cases where swallowing whole capsules or tablets may be difficult an alternative option may be provided.

Part 1C has 2 arms (Arm A and Arm B). There will be a total of approximately 16 participants to be enrolled into the 2 arms in Part 1C. Enrolment into Arm A will be sequential until Arm A is full then enrolment into Arm B will occur.

At Part 1C initiation, all participants will allocated to Arm A (2 different medications). Based on a review of safety data from Parts 1A, 1B, and available data from Arm A of Part 1C, the Sponsor may initiate a second treatment arm - Arm B (3 different medications).

Arm A: Approximately 8 participants will be allocated to receive RTX-101 treatment (comprised of 2 different medications). RTX-101 dosage to be determined based on Part 1A and Part 1B cohorts in healthy participants. There is a Safety Review Committee who will review all the data to determine the levels. There will only be one dose level for each of the 2 formulations in Arm A.

The minimum dose is 1 x 100mg tablet and 1 x 500mg capsule and maximum dose is 6 x 500mg capsules and 1 x 300mg tablet.

Arm B: Approximately 8 participants allocated to received RTX-111 treatment (comprised of 3 different medications). RTX-111 dosage to be determined based on Part 1A and Part 1B cohorts in healthy participants. There is a Safety Review Committee who will review all the data to determine the levels. There will only be one dose level for each of the 3 formulations in Arm B.

The minimum dose is 1 x 100mg tablet, 1 x 500mg capsule and 1 x 100mg capsule and maximum dose is 6 x 500mg capsules, 2 x 200mg capsules and 1 x 300mg tablet.

Participants will administer their allocated treatment two times daily for approximately 6 months.
Intervention code [1] 332908 0
Treatment: Drugs
Description of the comparator or control
In Part 1C all participants will receive the active treatment, there is not placebo treatment in Part 1C.

Both Arm A and Arm B are considered investigational which are looking primarily at the safety, tolerability and PK of the two different combinations.

The two arms (Arm A and Arm B) are not being compared to each other, there is no control or comparator group for Part 1C.
Control group
Uncontrolled

Outcomes
Primary outcome [1] 344011 0
To investigate the safety and tolerability of RTX-101 in adult patients with C9orf72-ALS following multiple oral dose administrations.
Timepoint [1] 344011 0
Vital signs: Blood pressure (systolic and diastolic), heart rate, respiratory rate using a blood pressure cuff and temperature using a thermometer will be measured at screening, Day -1, Day 1 pre-morning dose, 1.5 hour, 3 hour, pre-afternoon dose, 1.5 hour, 3 hour, Day 3, Day 5, Day 7 pre-morning dose, 1.5 hour, 3 hour, pre-afternoon dose, 1.5 hour, 3 hour, Day 30, Day 60, Day 90, Day 120, Day 150, Day 180 and Day 210. ECGs using an ECG machine will be measured at screening, Day -1, Day 1 pre-morning dose, 1.5 hour, 3 hour, pre-afternoon dose, 1.5 hour, 3 hour, Day 3, Day 5, Day 7 pre-morning dose, 1.5 hour, 3 hour, pre-afternoon dose, 1.5 hour, 3 hour, pre-dose, 1 hour, 3 hour, 6 hour, Day 30, Day 60, Day 90, Day 120, Day 150, Day 180 and Day 210. Safety Laboratory Tests (including biochemistry, haematology, coagulation and urinalysis - blood collected by either needle/syringe or cannula and urine sample will be collected at screening, Day -1, Day 1 pre-dose, Day 3, Day 5, Day 7, Day 30, Day 60, Day 90, Day 120, Day 150, Day 180 and Day 210.
Primary outcome [2] 344491 0
To investigate the safety and tolerability of RTX-111 in adult patients with C9orf72-ALS following multiple oral dose administrations.
Timepoint [2] 344491 0
ital signs: Blood pressure (systolic and diastolic), heart rate, respiratory rate using a blood pressure cuff and temperature using a thermometer will be measured at screening, Day -1, Day 1 pre-morning dose, 1.5 hour, 3 hour, pre-afternoon dose, 1.5 hour, 3 hour, Day 3, Day 5, Day 7 pre-morning dose, 1.5 hour, 3 hour, pre-afternoon dose, 1.5 hour, 3 hour, Day 30, Day 60, Day 90, Day 120, Day 150, Day 180 and Day 210. ECGs using an ECG machine will be measured at screening, Day -1, Day 1 pre-morning dose, 1.5 hour, 3 hour, pre-afternoon dose, 1.5 hour, 3 hour, Day 3, Day 5, Day 7 pre-morning dose, 1.5 hour, 3 hour, pre-afternoon dose, 1.5 hour, 3 hour, pre-dose, 1 hour, 3 hour, 6 hour, Day 30, Day 60, Day 90, Day 120, Day 150, Day 180 and Day 210. Safety Laboratory Tests (including biochemistry, haematology, coagulation and urinalysis - blood collected by either needle/syringe or cannula and urine sample will be collected at screening, Day -1, Day 1 pre-dose, Day 3, Day 5, Day 7, Day 30, Day 60, Day 90, Day 120, Day 150, Day 180 and Day 210.
Secondary outcome [1] 456449 0
To investigate the plasma pharmacokinetics (PK) characteristics of single ascending oral doses of RTX-101 in participants with C9orf72-mediated ALS
Timepoint [1] 456449 0
Blood PK samples are collected at Day 1 pre-morning dose, 1.5 hour, 3 hour, 4 hour, 6 hour, pre-afternoon dose, 9.5 hour, 12 hour, Day 2, Day3, Day 5 pre-dose, Day 7 pre-morning dose 1.5 hour, 3 hour, 4 hour, 6 hour, pre-afternoon dose, 9.5 hour, 12 hour, Day 8, Day 30, Day 60, Day 90, Day 120, Day 150, Day 180 and Day 210. Urine PK collection: a single urine sample at Day 1 pre-dose, Day 1: all urine samples within 0-4 hours, all urine samples within 4 to 12 hours, Day 7: all urine samples within 0-4 hours, all urine samples within 4 to 12 hours.
Secondary outcome [2] 458028 0
To investigate the plasma pharmacokinetics (PK) characteristics of single ascending oral doses of RTX-111 in participants with C9orf72-mediated ALS
Timepoint [2] 458028 0
Blood PK samples are collected at Day 1 pre-morning dose, 1.5 hour, 3 hour, 4 hour, 6 hour, pre-afternoon dose, 9.5 hour, 12 hour, Day 2, Day3, Day 5 pre-dose, Day 7 pre-morning dose 1.5 hour, 3 hour, 4 hour, 6 hour, pre-afternoon dose, 9.5 hour, 12 hour, Day 8, Day 30, Day 60, Day 90, Day 120, Day 150, Day 180 and Day 210. Urine PK collection: a single urine sample at Day 1 pre-dose, Day 1: all urine samples within 0-4 hours, all urine samples within 4 to 12 hours, Day 7: all urine samples within 0-4 hours, all urine samples within 4 to 12 hours.

Eligibility
Key inclusion criteria
1) Male or female participants, aged 18-70 years of age with diagnosis of ALS
2) Documented pathological repeat expansions in the intronic hexanucleotide repeat found in open reading frame 72 on chromosome 9 (C9orf72).
3) Time since first symptoms onset of ALS should be within 24-months at the time of screening
4) Participants taking riluzole (or other disease modifying medication) should be on a stable dose for at least 4 weeks prior to the screening visit. Participants are not allowed to start taking riluzole (or other disease modifying medication) until the completion of study.
5) Capable of providing informed consent. Each participant must sign an ICF indicating that he or she understands the purpose of procedures required for the trial and is willing to participate in the trial. Consent is to be obtained prior to the initiation of any trial-related tests or procedures that are not part of standard-of-care for the participant’s disease.
6) Capable and willing to undergo and follow trial procedures including visits to the trial clinic and visit requirements; in addition, must be willing and able to adhere to the prohibitions and restrictions specified in this protocol or has a competent caregiver/support person who can and will be able to support the individual's participation in the study, including assisting with the administration of study drug.
7) Females of childbearing potential must agree to use a highly effective method of contraception from the time of consent through at least 3 months after the last dose of study medication. Highly effective methods of contraception include intrauterine device, intrauterine system, contraceptive implant, combined injectable contraceptives, hormonal oral contraceptives when used in combination with male condoms. Sexual abstinence, defined as refraining from intercourse, when this is in line with the preferred and usual lifestyle of the participant. Remain exclusively in a same sex relationship, when this is in line with the preferred and usual lifestyle of the participant. Female participants with male partner(s) must either utilize highly effective forms of contraception or their male partner(s) must use a male condom.
8) Females of nonchildbearing potential must be postmenopausal (defined as a minimum of 12 consecutive months of spontaneous amenorrhea) or surgically sterile (hysterectomy, bilateral oophorectomy, or bilateral tubal ligation). Females of nonchildbearing potential are exempt from contraception requirements.
9) Males who are sexually active and whose partners are females of childbearing potential must agree to use male condoms from the time of consent through 3 months after administration of the last dose of study drug, and their partners must be willing to use a highly effective method of contraception from screening through 3 months after administration of the last dose of study drug. Males must agree not to donate sperm from screening through 3 months after administration of the last dose of study drug.
10) Must be fluent in English and have a degree of understanding sufficient to communicate suitably with the Investigator and the study coordinator.
Minimum age
18 Years
Maximum age
70 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
1) Known gout and/or treatment required gout and/or hyperuricaemia (defined as serum Uric Acid above the upper limit of normal with physiologic consequences).
2) Presence of tracheostomy or chronic mechanical ventilation (Note: Non-invasive ventilation such as CPAP and BiPAP are allowed).
3) Lung function – Slow Vital capacity (SVC) less than 50% at the time of screening.
4) History of known allergy, hypersensitivity, intolerance, and/or contraindication to the 3 investigational product formulations or their excipients.
5) Renal insufficiency at the time of screening as defined by Cystatin-C eGFR =60 mL/min/1.73m^2.
6) Pregnant women (confirmed by a pregnancy test within 7 days of first dose (Day 1)) or women currently breastfeeding.
7) History of Class III/IV heart failure (per New York Heart Association - NYHA) at screening.
8) Presence of unstable psychiatric disease as judged by the investigator.
9) Evidence of suicide risk, defined as 1) suicide attempt within 1 year prior to screening visit or 2) significant risk judged by the Investigator and the Columbia Suicide Severity Rating Scale (CSSRS).
10) Clinically significant unstable medical condition (other than ALS) (e.g., cardiovascular instability, systemic infection, untreated thyroid dysfunction, severe laboratory test anomaly or clinically significant electrocardiogram [ECG] changes) that would pose a risk to the participant if he/she were to participate in the trial, according to Investigator judgment.
11) Patients with abnormal iron storage caused by haemochromatosis that may lead to clinically significant outcomes in the opinion of the PI identified at screening (or any time prior to dosing).
12) Currently enrolled in another interventional trial.
13) Currently or previously treated within the last 14 days or planned exposure to any medications listed in Section 4.4.1 of the protocol.
14) History of positive test result for human immunodeficiency virus or hepatitis C virus
15) Current hepatitis B infection (defined as positive for hepatitis B surface antigen [HBsAg] and/or hepatitis B core antibody [HBcAb]). Participants with immunity to hepatitis B from previous natural infection (defined as negative HBsAg, positive hepatitis B surface antibody immunoglobulin G, and positive HBcAb) or vaccination (defined as positive anti-HBs) are eligible to participate in the trial.
16) Exclusionary safety laboratory values at screening:
a. Alanine aminotransferase (ALT) >3 × upper limit of normal (ULN)
b. Aspartate aminotransferase (AST) >3 × ULN
c. Total bilirubin >3 × ULN
d. Alkaline phosphatase (ALP) >3 × ULN
e. Creatinine > 1.5 x ULN
f. GFR =60mL/min/1,73m2 (calculated using the 2021 CKD-EPI Cystatin-C equation)
g. Platelet count 1.2 × ULN
i. Partial thromboplastin time (PTT) >1.2 × ULN

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is not concealed
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple allocation to each of the arms in Part 1C. Allocation to Arm A first. Randomisation has been removed from the description of intervention
Masking / blinding
Who is / are masked / blinded?



Intervention assignment
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,WA,VIC

Funding & Sponsors
Funding source category [1] 320863 0
Commercial sector/Industry
Name [1] 320863 0
Repeat Therapeutics Pty Ltd
Country [1] 320863 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Repeat Therapeutics Pty Ltd
Address
Country
Australia
Secondary sponsor category [1] 323541 0
None
Name [1] 323541 0
Address [1] 323541 0
Country [1] 323541 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319398 0
Monash Health Human Research Ethics Committee A
Ethics committee address [1] 319398 0
Ethics committee country [1] 319398 0
Australia
Date submitted for ethics approval [1] 319398 0
04/12/2025
Approval date [1] 319398 0
11/08/2026
Ethics approval number [1] 319398 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 147210 0
A/Prof Susan Mathers
Address 147210 0
Calvary Health Care Bethlehem 476 Kooyong Road Caulfield South Victoria 3162
Country 147210 0
Australia
Phone 147210 0
+61 3 9834 9000
Fax 147210 0
Email 147210 0
Contact person for public queries
Name 147211 0
Susan Francia
Address 147211 0
Repeat Therapeutics, Inc. 5639 Dolphin Pl. La Jolla, CA 92037
Country 147211 0
United States of America
Phone 147211 0
+1 267 968 4355
Fax 147211 0
Email 147211 0
Contact person for scientific queries
Name 147212 0
Susan Mathers
Address 147212 0
Calvary Health Care Bethlehem 476 Kooyong Road Caulfield South Victoria 3162
Country 147212 0
Australia
Phone 147212 0
+61 3 9834 9000
Fax 147212 0
Email 147212 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.